"Novo ambiente dá muitas razões de preocupação", avisa Lagarde. BCE "comprometido" com inflação

[Scubawarrior]

vamos agora ver nas próximas sessões se as noticias já estão incorporadas no preço ou não, visto estra a cair há bastante tempo


+DJ MedImmune Cuts 4Q, Year Views

11/17/2003
Dow Jones News Services
(Copyright © 2003 Dow Jones & Company, Inc.)



(MORE) Dow Jones Newswires

11-17-03 1930ET

*DJ MedImmune Cites Lower-Than-Expected FluMist Demand



(MORE) Dow Jones Newswires

11-17-03 1930ET

*DJ MedImmune Sees 2003 Adjusted EPS 72c-80c



(MORE) Dow Jones Newswires

11-17-03 1930ET

*DJ MedImmune Had Seen 2003 Adjusted EPS 88c-93c



(MORE) Dow Jones Newswires

11-17-03 1931ET

*DJ MedImmune Sees 2003 EPS 68c-76c; Had Seen 84c-89c



(MORE) Dow Jones Newswires

11-17-03 1931ET

*DJ MedImmune Sees 4Q Rev $385M-$445M; Had Seen $450M-$500M



(MORE) Dow Jones Newswires

11-17-03 1932ET

*DJ MedImmune Sees 4Q GAAP EPS 26c-34c, Had Seen 42c-47c



(MORE) Dow Jones Newswires

11-17-03 1932ET

DJ MedImmune Cuts Forecast-2: Evaluating Shortfall With Wyeth


GAITHERSBURG, Md. (Dow Jones)--MedImmune Inc. (MEDI) expects to miss its financial forecasts for the fourth quarter and full-year due to disappointing sales of FluMist, the influenza vaccine the company co-markets with Wyeth (WYE).

"I am disappointed to say that at this point, roughly half-way through the approximately twelve-week peak immunization season for FluMist, we have not seen the anticipated ramp up in demand," said Chief Executive David M. Mott in a press release Monday. "We are working with our partners at Wyeth to evaluate the reasons for the shortcomings and to develop our plan for the future.

MedImmune now expects full-year 2003 FluMist revenue of $55 million to $85 million, down from the company's previous target of $120 million to $140 million.


(MORE) Dow Jones Newswires

11-17-03 1955ET

DJ MedImmune Cuts Forecast -3: Street Sees 4Q EPS 46c >MEDI


For the fourth quarter, MedImmune has lowered its earnings target to 26 cents to 34 cents a share, compared with the previous target range of 42 cents to 47 cents. The company now expects earnings, before acquisition expenses, of 28 cents to 36 cents a share.

A Thomson First Call survey of 23 analysts puts fourth-quarter earnings at 46 cents a share, compared with 47 cents a share MedImmune earned a year ago, before items.

Total revenue is now slated at $385 million to $445 million, MedImmune said, down from $450 million to $500 million forecast earlier.

For the full year, MedImmune expects revenue of $1.04 billion to $1.1 billion, down from previously stated guidance of $1.1 billion to $1.15 billion.

Adjusted earnings per diluted share for 2003 are now expected to range from 72 cents to 80 cents a share, compared with prior guidance of 88 cents to 93 cents. Bottom-line earnings are now expected to be 68 cents to 76 cents a share, versus prior guidance of 84 cents to 89 cents.

Analysts are looking for 2003 earnings of 90 cents a share and revenue of $1.13 billion.


(MORE) Dow Jones Newswires


cmps